{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:35:19Z","timestamp":1786707319491,"version":"build-2736575974"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic eosinophilic pneumonia (CEP) is a rare, idiopathic inflammatory lung disease characterized by subacute symptoms such as cough, dyspnea, and fever; abnormal chest imaging findings; peripheral eosinophilia; and eosinophilic infiltration of the pulmonary interstitium and alveoli. Eosinophils interact with multiple T helper 2 (Th2) cellular pathways; however, eosinophil recruitment to the lung is primarily mediated by interleukin (IL)-5 and the eotaxin subfamily of chemokines. Standard treatment consists of systemic corticosteroids; however, relapse is frequent after tapering the corticosteroid dose, leading to long-term steroid therapy and its associated adverse effects, including diabetes mellitus, infections, glaucoma, and osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This narrative review aims to summarize the available evidence on the effectiveness and safety of anti\u2013IL-5 biologic therapies (mepolizumab, reslizumab, and benralizumab) in the management of CEP and as steroid-sparing strategies, with particular focus on their role in relapse prevention, which occurs in nearly 50% of cases during systemic corticosteroid tapering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was conducted to identify the real-world advances of anti-IL-5 treatments in CEP. Most of the available literature consists of case series, case reports and observational studies, owing to the lack of controlled clinical trials and guidelines involving this disease and anti\u2013IL-5 therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The available evidence suggests that anti\u2013IL-5 therapies are effective in controlling disease activity, reducing relapse rates, and enabling corticosteroid tapering or discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All the treatments considered were safe and well tolerated, and their use provided significant benefits in terms of symptom control, despite the limited impact on pulmonary function. Owing to their steroid-sparing effects, these agents are useful in reducing the adverse effects associated with long-term corticosteroid use. Anti\u2013IL-5 biologics represent a promising therapeutic option for patients with relapsing or corticosteroid-dependent CEP. Despite encouraging results, larger prospective studies are needed to better define their role in the long-term management of this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1893402","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:05:23Z","timestamp":1786705523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies"],"prefix":"10.3389","volume":"17","author":[{"given":"Chiara","family":"Scelfo","sequence":"first","affiliation":[{"name":"Pulmonology Unit, Arcispedale Santa Maria Nuova, Azienda USL - IRCCS di Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Simonazzi","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Arcispedale Santa Maria Nuova, Azienda USL - IRCCS di Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Arcispedale Santa Maria Nuova, Azienda USL - IRCCS di Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Arcispedale Santa Maria Nuova, Azienda USL - IRCCS di Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Facciolongo","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Arcispedale Santa Maria Nuova, Azienda USL - IRCCS di Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2025.07.007","article-title":"Eosinophilic lung diseases","volume":"37","author":"Cottin","year":"2016","journal-title":"Clin Chest Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.08.009","article-title":"Persistent impairment on spirometry in chronic eosinophilic pneumonia. A longitudinal observation study","volume":"119","author":"Suzuki","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10020286","article-title":"Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia","volume":"10","author":"Durieu","year":"1997","journal-title":"Eur Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810150","article-title":"Eosinophils as drivers of severe eosinophilic asthma: Endotypes or plasticity","volume":"22","author":"Van Hulst","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.025","article-title":"Human versus mouse eosinophils: \u201cthat which we call an eosinophil, by any other name would stain as red","volume":"130","author":"Lee","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.002","article-title":"A tribute to eosinophils from a comparative and evolutionary perspective","volume":"147","author":"Stacy","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.02.031","article-title":"The eosinophil","volume":"121","author":"Bochner","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B8","unstructured":"Eosinophils in health and disease: A state-of-the-art review\n          \n          \n            \n              Wechsler\n              ME\n            \n            \n              Munitz\n              A\n            \n            \n              Ackerman\n              SJ\n            \n            \n              Drake\n              MG\n            \n            \n              Jackson\n              DJ\n            \n            \n              Wardlaw\n              AJ\n            \n          \n          \n          2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/jlb.1mr1117-442rr","article-title":"Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease","volume":"104","author":"Abdala-Valencia","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s42255-020-0228-3","article-title":"Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age","volume":"2","author":"Brigger","year":"2020","journal-title":"Nat Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.3mr1117-426r","article-title":"Eosinophil and airway nerve interactions in asthma","volume":"104","author":"Drake","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600611","article-title":"IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis","volume":"197","author":"Johnston","year":"2016","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443424","article-title":"Use of 111-indium\u2013labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects","volume":"120","author":"Farahi","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.r113.546218","article-title":"Eosinophil granule proteins: form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.14670\/HH-25.1341","article-title":"Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying in-flammatory responses","volume":"25","author":"Melo","year":"2010","journal-title":"Histol Histopathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.43409","article-title":"Interleukin (IL)-5, eosinophils and IL-5 pathway inhibitors in eosinophilic granulomatosis with polyangiitis","volume":"78","author":"Berti","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/all.14297","article-title":"Human airway epithelial cells express a functional IL- 5 receptor","volume":"75","author":"Barretto","year":"2020","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/all.15627","article-title":"IL- 5 receptor expression in lung fibroblasts: potential role in airway remodeling in asthma","volume":"78","author":"Bajbouj","year":"2023","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000235355","article-title":"IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD1 1\/18)-dependent manner","volume":"71","author":"Walsh","year":"1990","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1165\/rcmb.2005-0076oc","article-title":"Regulation of interleukin-5-induced \u03b22-integrin adhesion of human eosinophils by phosphoinositide 3 kinase","volume":"33","author":"Sano","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0800864","article-title":"A role for Bid in eosinophil apoptosis and in allergic airway reaction","volume":"182","author":"Maret","year":"2009","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.03.004","article-title":"Group 2 innate lymphoid cells and asthma","volume":"64","author":"Kabata","year":"2015","journal-title":"Allergology Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: From discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.7.2014","article-title":"Transduction of a dominant-negative H-Ras into human eosinophils attenuates extracellular signal-regulated kinase activation and interleukin-5-mediated cell viability","volume":"98","author":"Hall","year":"2001","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biom10040638","article-title":"Possible mechanism of eosinphil accumulation in eosinophilic pneumonia","volume":"10","author":"Nakagome","year":"2020","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02220","article-title":"Involvement and possible role of eosinophils in asthma exacerbation","volume":"18","author":"Nakagome","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cyto.2016.11.011","article-title":"Allergic diseases: From bench to clinic-contribution of the discovery of interleukin-5","volume":"98","author":"Yanagibashi","year":"2017","journal-title":"Cytokine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.109827","article-title":"Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia","volume":"106","author":"Katoh","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2332\/allergolint.12-oa-0439","article-title":"Clinical significance of interleukin 33 (IL-33) in patients with eosinophilic pneumonia","volume":"62","author":"Mato","year":"2013","journal-title":"Allergol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.13-rai-0663","article-title":"Periostin in allergic inflammation","volume":"63","author":"Izuhara","year":"2014","journal-title":"Allergol Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.41982","article-title":"2022 American college of rheumatology\/european alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/196141","article-title":"A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review","volume":"62","author":"Sebastian","year":"2024","journal-title":"Reumatologia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00199614","article-title":"Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia","volume":"45","author":"Oyama","year":"2015","journal-title":"Eur Respir J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000072898","article-title":"Chronich eosinophilic pneumonia: Treatment with inhaled corticosteroids","volume":"70","author":"Minakuchi","year":"2003","journal-title":"Respiration"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i18.6105","article-title":"Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report","volume":"10","author":"Izhakian","year":"2022","journal-title":"World J Clin cases"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.70515","article-title":"Six-month benralizumab maintenance for relapsing chronic eosinophilic pneumonia guided by eosinophil kinetics","volume":"14","author":"Sumi","year":"2026","journal-title":"Respirology Case Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12890-024-02868-3","article-title":"Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: A scoping review","volume":"24","author":"Murillo","year":"2024","journal-title":"BMC Pulm Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07081541","article-title":"Chronic eosinophilic pneumonia progressing to lung fibrosis","volume":"7","author":"Yoshida","year":"1994","journal-title":"Eur Respir J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-5-3","article-title":"Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucorticosteroid intolerance","volume":"9","author":"Kisling","year":"2020","journal-title":"Drugs Context"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/biologics5030023","article-title":"Fibrotic chronic eosinophilic pneumonia treated with an anti IL-5 monoclonal antibody: A case report","volume":"5","author":"Semenzato","year":"2025","journal-title":"Biologics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.06.053","article-title":"Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report","volume":"8","author":"Ciuffreda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","article-title":"A case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.alit.2022.10.004","article-title":"Treatments of refractory eosinophilic lung diseases with biologics","volume":"72","author":"Asano","year":"2023","journal-title":"Allergology Int"},{"key":"B52","doi-asserted-by":"publisher","first-page":"A1273","DOI":"10.1016\/j.chest.2021.07.1160","article-title":"When steroids fail: a population-based review of biologic therapies in the management of recalcitrant eosinophilic pneumonia","volume":"160","author":"Askin","year":"2021","journal-title":"CHEST Ann Meet Orig Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S157882","article-title":"Chronic eosinophilic pneumonia: clinical perspectives","volume":"15","author":"Crowe","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v39i2.12656","article-title":"Idiopathic chronic eosinophilic pneumonia evolving to pulmonary fibrosis: a retrospective analysis: eosinophilic pneumonia and fibrosis","volume":"39","author":"Baqir","year":"2022","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399st","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10020286","article-title":"Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia","volume":"10","author":"Durieu","year":"1997","journal-title":"Groupe d'\u00c9tude en Pathologie Interstitielle de la Soci\u00e9t\u00e9 de Pathologie Thoracique du Nord Eur Respir J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S343272","article-title":"Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a case series","volume":"15","author":"Tashiro","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yakawa","year":"2021","journal-title":"Allergology Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"101062","DOI":"10.1016\/j.rmcr.2020.101062","article-title":"Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia","volume":"30","author":"Zumo","year":"2020","journal-title":"Respirology Med Case Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0671","article-title":"Efficacy of mepolizumab extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia","volume":"31","author":"Sato","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/02770903.2023.2239343","article-title":"Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing","volume":"61","author":"Prieto-Garcia","year":"2024","journal-title":"J Asthma"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:05:25Z","timestamp":1786705525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2026.1893402"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893402","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1893402"}}